Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Identifieur interne : 001E87 ( PubMed/Corpus ); précédent : 001E86; suivant : 001E88Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Auteurs : A. Hochhaus ; G. Saglio ; T P Hughes ; R A Larson ; D-W Kim ; S. Issaragrisil ; P D Le Coutre ; G. Etienne ; P E Dorlhiac-Llacer ; R E Clark ; I W Flinn ; H. Nakamae ; B. Donohue ; W. Deng ; D. Dalal ; H D Menssen ; H M KantarjianSource :
- Leukemia [ 1476-5551 ] ; 2016.
English descriptors
- KwdEn :
- Blood Glucose (metabolism), Cholesterol (blood), Follow-Up Studies, Humans, Imatinib Mesylate (administration & dosage), Imatinib Mesylate (pharmacology), Leukemia, Myelogenous, Chronic, BCR-ABL Positive (blood), Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy), Leukemia, Myelogenous, Chronic, BCR-ABL Positive (mortality), Leukemia, Myeloid, Chronic-Phase (blood), Leukemia, Myeloid, Chronic-Phase (drug therapy), Leukemia, Myeloid, Chronic-Phase (mortality), Pyrimidines (administration & dosage), Pyrimidines (pharmacology), Risk Assessment, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Imatinib Mesylate, Pyrimidines.
- chemical , blood : Cholesterol.
- chemical , metabolism : Blood Glucose.
- chemical , pharmacology : Imatinib Mesylate, Pyrimidines.
- blood : Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase.
- drug therapy : Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase.
- mortality : Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase.
- Follow-Up Studies, Humans, Risk Assessment, Treatment Outcome.
Abstract
In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Here, patients' long-term outcomes in ENESTnd are evaluated after a minimum follow-up of 5 years. By 5 years, more than half of all patients in each nilotinib arm (300 mg twice daily, 54%; 400 mg twice daily, 52%) achieved a molecular response 4.5 (MR(4.5); BCR-ABL⩽0.0032% on the International Scale) compared with 31% of patients in the imatinib arm. A benefit of nilotinib was observed across all Sokal risk groups. Overall, safety results remained consistent with those from previous reports. Numerically more cardiovascular events (CVEs) occurred in patients receiving nilotinib vs imatinib, and elevations in blood cholesterol and glucose levels were also more frequent with nilotinib. In contrast to the high mortality rate associated with CML progression, few deaths in any arm were associated with CVEs, infections or pulmonary diseases. These long-term results support the positive benefit-risk profile of frontline nilotinib 300 mg twice daily in patients with CML-CP.
DOI: 10.1038/leu.2016.5
PubMed: 26837842
Links to Exploration step
pubmed:26837842Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.</title><author><name sortKey="Hochhaus, A" sort="Hochhaus, A" uniqKey="Hochhaus A" first="A" last="Hochhaus">A. Hochhaus</name><affiliation><nlm:affiliation>Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Saglio, G" sort="Saglio, G" uniqKey="Saglio G" first="G" last="Saglio">G. Saglio</name><affiliation><nlm:affiliation>Division of Internal Medicine & Hematology, University of Turin, Orbassano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Hughes, T P" sort="Hughes, T P" uniqKey="Hughes T" first="T P" last="Hughes">T P Hughes</name><affiliation><nlm:affiliation>South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, SA Pathology, Adelaide, South Australia, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Larson, R A" sort="Larson, R A" uniqKey="Larson R" first="R A" last="Larson">R A Larson</name><affiliation><nlm:affiliation>Department of Medicine, The University of Chicago, Chicago, IL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, D W" sort="Kim, D W" uniqKey="Kim D" first="D-W" last="Kim">D-W Kim</name><affiliation><nlm:affiliation>Leukemia Research Institute, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Issaragrisil, S" sort="Issaragrisil, S" uniqKey="Issaragrisil S" first="S" last="Issaragrisil">S. Issaragrisil</name><affiliation><nlm:affiliation>Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Le Coutre, P D" sort="Le Coutre, P D" uniqKey="Le Coutre P" first="P D" last="Le Coutre">P D Le Coutre</name><affiliation><nlm:affiliation>Charité-Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Etienne, G" sort="Etienne, G" uniqKey="Etienne G" first="G" last="Etienne">G. Etienne</name><affiliation><nlm:affiliation>Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, Institut Bergonié, Département d'Oncologie Médicale, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dorlhiac Llacer, P E" sort="Dorlhiac Llacer, P E" uniqKey="Dorlhiac Llacer P" first="P E" last="Dorlhiac-Llacer">P E Dorlhiac-Llacer</name><affiliation><nlm:affiliation>Hospital das Clinicas FMUSP, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Clark, R E" sort="Clark, R E" uniqKey="Clark R" first="R E" last="Clark">R E Clark</name><affiliation><nlm:affiliation>Royal Liverpool University Hospital, Liverpool, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Flinn, I W" sort="Flinn, I W" uniqKey="Flinn I" first="I W" last="Flinn">I W Flinn</name><affiliation><nlm:affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nakamae, H" sort="Nakamae, H" uniqKey="Nakamae H" first="H" last="Nakamae">H. Nakamae</name><affiliation><nlm:affiliation>Department of Hematology, Osaka City University, Osaka, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Donohue, B" sort="Donohue, B" uniqKey="Donohue B" first="B" last="Donohue">B. Donohue</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Deng, W" sort="Deng, W" uniqKey="Deng W" first="W" last="Deng">W. Deng</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dalal, D" sort="Dalal, D" uniqKey="Dalal D" first="D" last="Dalal">D. Dalal</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Menssen, H D" sort="Menssen, H D" uniqKey="Menssen H" first="H D" last="Menssen">H D Menssen</name><affiliation><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Kantarjian, H M" sort="Kantarjian, H M" uniqKey="Kantarjian H" first="H M" last="Kantarjian">H M Kantarjian</name><affiliation><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26837842</idno><idno type="pmid">26837842</idno><idno type="doi">10.1038/leu.2016.5</idno><idno type="wicri:Area/PubMed/Corpus">001E87</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E87</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.</title><author><name sortKey="Hochhaus, A" sort="Hochhaus, A" uniqKey="Hochhaus A" first="A" last="Hochhaus">A. Hochhaus</name><affiliation><nlm:affiliation>Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Saglio, G" sort="Saglio, G" uniqKey="Saglio G" first="G" last="Saglio">G. Saglio</name><affiliation><nlm:affiliation>Division of Internal Medicine & Hematology, University of Turin, Orbassano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Hughes, T P" sort="Hughes, T P" uniqKey="Hughes T" first="T P" last="Hughes">T P Hughes</name><affiliation><nlm:affiliation>South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, SA Pathology, Adelaide, South Australia, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Larson, R A" sort="Larson, R A" uniqKey="Larson R" first="R A" last="Larson">R A Larson</name><affiliation><nlm:affiliation>Department of Medicine, The University of Chicago, Chicago, IL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, D W" sort="Kim, D W" uniqKey="Kim D" first="D-W" last="Kim">D-W Kim</name><affiliation><nlm:affiliation>Leukemia Research Institute, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Issaragrisil, S" sort="Issaragrisil, S" uniqKey="Issaragrisil S" first="S" last="Issaragrisil">S. Issaragrisil</name><affiliation><nlm:affiliation>Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Le Coutre, P D" sort="Le Coutre, P D" uniqKey="Le Coutre P" first="P D" last="Le Coutre">P D Le Coutre</name><affiliation><nlm:affiliation>Charité-Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Etienne, G" sort="Etienne, G" uniqKey="Etienne G" first="G" last="Etienne">G. Etienne</name><affiliation><nlm:affiliation>Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, Institut Bergonié, Département d'Oncologie Médicale, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dorlhiac Llacer, P E" sort="Dorlhiac Llacer, P E" uniqKey="Dorlhiac Llacer P" first="P E" last="Dorlhiac-Llacer">P E Dorlhiac-Llacer</name><affiliation><nlm:affiliation>Hospital das Clinicas FMUSP, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Clark, R E" sort="Clark, R E" uniqKey="Clark R" first="R E" last="Clark">R E Clark</name><affiliation><nlm:affiliation>Royal Liverpool University Hospital, Liverpool, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Flinn, I W" sort="Flinn, I W" uniqKey="Flinn I" first="I W" last="Flinn">I W Flinn</name><affiliation><nlm:affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nakamae, H" sort="Nakamae, H" uniqKey="Nakamae H" first="H" last="Nakamae">H. Nakamae</name><affiliation><nlm:affiliation>Department of Hematology, Osaka City University, Osaka, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Donohue, B" sort="Donohue, B" uniqKey="Donohue B" first="B" last="Donohue">B. Donohue</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Deng, W" sort="Deng, W" uniqKey="Deng W" first="W" last="Deng">W. Deng</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dalal, D" sort="Dalal, D" uniqKey="Dalal D" first="D" last="Dalal">D. Dalal</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Menssen, H D" sort="Menssen, H D" uniqKey="Menssen H" first="H D" last="Menssen">H D Menssen</name><affiliation><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Kantarjian, H M" sort="Kantarjian, H M" uniqKey="Kantarjian H" first="H M" last="Kantarjian">H M Kantarjian</name><affiliation><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Leukemia</title><idno type="eISSN">1476-5551</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Glucose (metabolism)</term><term>Cholesterol (blood)</term><term>Follow-Up Studies</term><term>Humans</term><term>Imatinib Mesylate (administration & dosage)</term><term>Imatinib Mesylate (pharmacology)</term><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (blood)</term><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)</term><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (mortality)</term><term>Leukemia, Myeloid, Chronic-Phase (blood)</term><term>Leukemia, Myeloid, Chronic-Phase (drug therapy)</term><term>Leukemia, Myeloid, Chronic-Phase (mortality)</term><term>Pyrimidines (administration & dosage)</term><term>Pyrimidines (pharmacology)</term><term>Risk Assessment</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Imatinib Mesylate</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cholesterol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Imatinib Mesylate</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term><term>Leukemia, Myeloid, Chronic-Phase</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term><term>Leukemia, Myeloid, Chronic-Phase</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term><term>Leukemia, Myeloid, Chronic-Phase</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Follow-Up Studies</term><term>Humans</term><term>Risk Assessment</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Here, patients' long-term outcomes in ENESTnd are evaluated after a minimum follow-up of 5 years. By 5 years, more than half of all patients in each nilotinib arm (300 mg twice daily, 54%; 400 mg twice daily, 52%) achieved a molecular response 4.5 (MR(4.5); BCR-ABL⩽0.0032% on the International Scale) compared with 31% of patients in the imatinib arm. A benefit of nilotinib was observed across all Sokal risk groups. Overall, safety results remained consistent with those from previous reports. Numerically more cardiovascular events (CVEs) occurred in patients receiving nilotinib vs imatinib, and elevations in blood cholesterol and glucose levels were also more frequent with nilotinib. In contrast to the high mortality rate associated with CML progression, few deaths in any arm were associated with CVEs, infections or pulmonary diseases. These long-term results support the positive benefit-risk profile of frontline nilotinib 300 mg twice daily in patients with CML-CP.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26837842</PMID><DateCreated><Year>2016</Year><Month>05</Month><Day>04</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5551</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Leukemia</Title><ISOAbbreviation>Leukemia</ISOAbbreviation></Journal><ArticleTitle>Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.</ArticleTitle><Pagination><MedlinePgn>1044-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2016.5</ELocationID><Abstract><AbstractText>In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Here, patients' long-term outcomes in ENESTnd are evaluated after a minimum follow-up of 5 years. By 5 years, more than half of all patients in each nilotinib arm (300 mg twice daily, 54%; 400 mg twice daily, 52%) achieved a molecular response 4.5 (MR(4.5); BCR-ABL⩽0.0032% on the International Scale) compared with 31% of patients in the imatinib arm. A benefit of nilotinib was observed across all Sokal risk groups. Overall, safety results remained consistent with those from previous reports. Numerically more cardiovascular events (CVEs) occurred in patients receiving nilotinib vs imatinib, and elevations in blood cholesterol and glucose levels were also more frequent with nilotinib. In contrast to the high mortality rate associated with CML progression, few deaths in any arm were associated with CVEs, infections or pulmonary diseases. These long-term results support the positive benefit-risk profile of frontline nilotinib 300 mg twice daily in patients with CML-CP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hochhaus</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saglio</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Internal Medicine & Hematology, University of Turin, Orbassano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>T P</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, SA Pathology, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>D-W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Leukemia Research Institute, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Issaragrisil</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>le Coutre</LastName><ForeName>P D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Charité-Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etienne</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, Institut Bergonié, Département d'Oncologie Médicale, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorlhiac-Llacer</LastName><ForeName>P E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Hospital das Clinicas FMUSP, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>R E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Royal Liverpool University Hospital, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flinn</LastName><ForeName>I W</ForeName><Initials>IW</Initials><AffiliationInfo><Affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamae</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Osaka City University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalal</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menssen</LastName><ForeName>H D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantarjian</LastName><ForeName>H M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Leukemia</MedlineTA><NlmUniqueID>8704895</NlmUniqueID><ISSNLinking>0887-6924</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498826">4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8A1O1M485B</RegistryNumber><NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Feb 24;117(8):e75-87</RefSource><PMID Version="1">20810928</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2013 Jun;27(6):1310-5</RefSource><PMID Version="1">23459450</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Jan 20;30(3):232-8</RefSource><PMID Version="1">22067393</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2012 May 1;125(17):2128-37</RefSource><PMID Version="1">22451584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2012 Jul;33(13):1635-701</RefSource><PMID Version="1">22555213</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2012 Sep;26(9):2096-102</RefSource><PMID Version="1">22446502</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2012 Oct;26(10):2197-203</RefSource><PMID Version="1">22699418</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2013 May 2;121(18):3703-8</RefSource><PMID Version="1">23502220</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Atheroscler Thromb. 2013;20(5):465-71</RefSource><PMID Version="1">23385059</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2013 Jun;27(6):1316-21</RefSource><PMID Version="1">23459449</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2016 Jan;30(1):57-64</RefSource><PMID Version="1">26437782</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2013 Jun 13;121(24):4867-74</RefSource><PMID Version="1">23620574</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2013 Aug 8;122(6):872-84</RefSource><PMID Version="1">23803709</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stroke. 2014 Jan;45(1):48-53</RefSource><PMID Version="1">24253542</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2014 Jan 15;20(2):310-22</RefSource><PMID Version="1">24166905</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 Jan 23;123(4):494-500</RefSource><PMID Version="1">24311723</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Feb 10;32(5):415-23</RefSource><PMID Version="1">24297946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 Feb 27;123(9):1353-60</RefSource><PMID Version="1">24335106</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 1994 Jan;8(1):186-9</RefSource><PMID Version="1">8289486</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2008 Feb 12;117(6):743-53</RefSource><PMID Version="1">18212285</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2009 Oct;94(10):1362-7</RefSource><PMID Version="1">19713230</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Compr Canc Netw. 2009 Oct;7(9):984-1023</RefSource><PMID Version="1">19878641</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Jun 17;362(24):2251-9</RefSource><PMID Version="1">20525993</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2011 Jan;34 Suppl 1:S11-61</RefSource><PMID Version="1">21193625</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2014 Mar;99(3):458-64</RefSource><PMID Version="1">24362549</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45</RefSource><PMID Version="1">24222016</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2014 Jul;99(7):1204-11</RefSource><PMID Version="1">24532039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Hematol. 2014 Oct;89(10):947-53</RefSource><PMID Version="1">24944159</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Hematol. 2015 Mar;94(3):393-7</RefSource><PMID Version="1">25304102</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cardiovasc Diabetol. 2015;14:14</RefSource><PMID Version="1">25645749</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2011 Sep;12(9):841-51</RefSource><PMID Version="1">21856226</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068877" MajorTopicYN="N">Imatinib Mesylate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015464" MajorTopicYN="N">Leukemia, Myelogenous, Chronic, BCR-ABL Positive</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015466" MajorTopicYN="N">Leukemia, Myeloid, Chronic-Phase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4858585</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>01</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26837842</ArticleId><ArticleId IdType="pii">leu20165</ArticleId><ArticleId IdType="doi">10.1038/leu.2016.5</ArticleId><ArticleId IdType="pmc">PMC4858585</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001E87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26837842
|texte= Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26837842" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |